What Will Happen To Coverage Of Covid-19 Tests, Vaccines, And Treatments Once The Government Is No Longer The Predominant Purchaser?

Healthcare What Will Happen To Coverage Of Covid-19 Tests, Vaccines, And Treatments Once The Government Is No Longer The Predominant Purchaser? Joshua Cohen Contributor Opinions expressed by Forbes Contributors are their own. I write about prescription drug value, market access, healthcare systems, and ethics of distribution of healthcare resources Following New! Follow this author to stay notified about their latest stories. Got it! Sep 5, 2022, 10:18am EDT | New! Click on the conversation bubble to join the conversation Got it! Share to Facebook Share to Twitter Share to Linkedin White House Covid-19 Response Coordinator Ashish Jha speaks during the daily briefing in the Brady .

. . [+] Briefing Room of the White House in Washington, DC, on July 22, 2022.

(Photo by MANDEL NGAN / AFP) (Photo by MANDEL NGAN/AFP via Getty Images) AFP via Getty Images In August, the Biden Administration announced it will stop being the predominant purchaser of Covid-19 vaccines, treatments, and tests at some point this autumn, as it moves “beyond the crisis phase of the pandemic. ” White House Covid-19 Response Team coordinator Dr. Ashish Jha said his “hope is that in 2023, you’re going to see the commercialization of almost all of these products.

” One product that will not be impacted by this change in procurement policy is the updated Omicron BA. 5-specific vaccine. The Biden Administration has signed purchase agreements for these vaccine doses.

Therefore, these will still be available this autumn universally in the same way previous vaccines and boosters were. Since the beginning of the Covid-19 pandemic the U. S.

federal government has been the predominant purchaser of Covid-19 tests, vaccines, and treatments. By doing so, it made possible population-wide access to testing, vaccination, and treatments. But now that will end.

We caught a glimpse of things to come when in August, Eli Lilly announced it was about to begin “commercial sales” of its Covid-19 monoclonal antibody bebtelovimab. Previously, the treatment was sold to the federal government, which oversaw its distribution to states and pharmacies and guaranteed free usage to patients. Fully reimbursed access to products like bebtelovimab will no longer be guaranteed to all.

The uninsured will be the most affected by the change in policy, followed by the commercially insured. There will be mitigated impacts in the public sectors of Medicare and Medicaid. MORE FOR YOU CDC: Salmonella Outbreak Has Left 279 Ill, 26 Hospitalized In 29 States Canadians End Up In ICU After Attending ‘Covid Party’ White House Mandates Pfizer Vaccines for Millions of Citizens .

. . Before the FDA Clinical or Safety Reviews Have Been Made Public Medicare and Medicaid will reimburse vaccinations for their beneficiaries between now and December 31st.

Afterwards, under a provision of the Inflation Reduction Act, Medicare will continue to pay for vaccinations in full, but not necessarily all tests or treatments. The Inflation Reduction Act eliminates Medicare beneficiary cost sharing for adult vaccines covered under Medicare Part D, as of 2023, Starting January 1, 2023, all Medicare Part D plans will be required to cover all adult vaccines recommended by the CDC’s Advisory Committee on Immunization Practices, with no cost sharing, even if the beneficiary is in the deductible phase of the benefit. Of note, once the Public Health Emergency (PHE) expires – which it may as soon as next month – it’s probable that many Medicare plans will drop near-universal coverage of Covid-19 tests that beneficiaries wish to take.

Instead, they will institute measures such as quantity limits and perhaps even prior authorization protocols as a precondition of coverage. During the Covid-19 PHE and for one year after it ends, Medicaid is required to cover Covid-19 testing, vaccinations, and treatment for practically all enrollees, free of charge. The commercial insurance sector – largely responsible for coverage of the 18-65 age group (except for disabled people and those who are Medicaid-eligible) – will make individual decisions on coverage of tests, vaccines, and treatments.

Most commercial insurers will discontinue universal coverage of tests. In lieu of blanket coverage, they will likely establish conditions of reimbursement, such as patient cost-sharing, quantity limits and prior authorization protocols which may prevent people from reimbursed access to tests, under certain circumstances. For vaccines, some commercial insurers could introduce patient cost-sharing for enrollees considered not at risk, but impose no cost-sharing for at-risk groups.

For treatments, there will be patient cost-sharing for most enrollees, as is the case for virtually all prescription drugs. There may also be age- and other restrictions on the use of treatments, such as the anti-viral Paxlovid (nirmatrelvir/ritonavir). As a result of the halt to federal government purchasing of Covid-19 tests, vaccines, and treatments, the most impacted sub-population will be the 8% of the U.

S. population who are uninsured. They will no longer have free access.

Perhaps the federal and state governments will intervene to finance access for the uninsured. Indeed, the Biden Administration is considering ways to ensure that the uninsured will still be able to obtain fully reimbursed Covid-19 resources. But, at present, this is far from certain, as Congressional funding would be necessary.

Throughout the pandemic, the federal government has provided Americans with Covid-19 tests, vaccines, and treatments free of charge, but this will soon change as there will be a transition from federal government to health insurer purchasing in both the public and private markets. The shift towards “commercialization” will come in stages, with, initially, protections in place in both the Medicaid and Medicare programs. However, in both Medicare and the commercial sector there will no longer be blanket coverage of tests, vaccines, and treatments, without, in certain instances, accompanying conditions of reimbursement, such as cost sharing and the institution of prior authorization protocols.

Furthermore, one year after the PHE terminates, Medicaid will no longer be obligated to cover all these products without restrictions. In turn, inequities – typically inherent to the U. S.

healthcare system – will inevitably arise. Follow me on Twitter . Joshua Cohen Editorial Standards Print Reprints & Permissions.